In my current role, I lead the early Oncology Projects group, 谁负责开发免疫肿瘤学(IO)药物, antibody drug conjugates (ADCs) and cell therapies 从临床前评估到3期临床试验.

Since joining AstraZeneca in 2016, 我领导了一系列探索IO制剂和溶瘤病毒以及癌症个性化治疗潜力的项目. 我还担任头颈部和肺癌肿瘤策略小组的科学负责人. Notably, I led the development strategy for our NGK2A agent, monalizumab, 现在已经进入了第三阶段的开发，并管理了澳门葡京赌博游戏与Innate Pharma合作的关键方面.  因为澳门葡京赌博游戏致力于从澳门葡京网赌游戏内部或外部寻求最好的科学, I have also lead collaborations including, Immunocore, Juno, Parker Institute, Transgene, Fred Hutch, Washington University Personalized Immunotherapy Collaboration. Prior to joining AstraZeneca, 我在百时美施贵宝公司(Bristol-Myers Squibb)担任的职位资历越来越高, Daiichi Sankyo and Amgen.

Throughout my nearly 25-year career, 我在肿瘤学领域从事过广泛的小分子和抗体项目, with a focus on biology, translational medicine and early development.

In this time, 我领导并建立了多个跨职能的发现和开发团队, 汇集不同背景和经验的同事, 旨在提供具有生产有效癌症药物的最大潜力的强大组合. 我特别自豪的是，我的同事们在澳门葡京赌博游戏行业的职业生涯中取得了进步.

我在加州大学获得了分子和医学药理学博士学位, 他获得了加州大学药理学学士学位, Santa Barbara. 我撰写了100多篇关于癌症研究的论文和会议摘要, and have generated 10 patents.

通过了解先天免疫系统和肿瘤之间的相互作用, 澳门葡京赌博游戏正在寻找利用免疫机制检测和根除癌细胞的新途径.

Daniel Freeman Vice President, Early Development Oncology

CURRENT ROLE

Vice-President, Projects, Oncology R&D, Research & Early Development, AstraZeneca

2014-2016

将生物标志物组的规模扩大了一倍，以满足不断增长的肿瘤管道(包括IO和非IO肿瘤资产)的需求, Oncology Biomarkers, Bristol-Myers Squibb

2012-2014

在Daiichi Sankyo的临床开发中承担越来越多的责任, 包括领导所有资产的转化研究策略的创建和实施, 重组生物标志物发现和开发组织, 并形成了一个肿瘤学战略，定义了公司对抗体药物偶联物的关注

2003-2012

While serving in oncology research scientist roles at Amgen, built the company’s first molecular/translational lab, 担任panitumumab的研究领导-发现和开发患者分层(KRAS)的生物标志物, served as Project Lead for patritumab, an anti-HER3 antibody-drug conjugate, 并领导了20多个许可机会的科学尽职调查

Featured publications

微生物疗法在癌症免疫治疗中的干预策略

V. Gopalakrishnan, B. Weiner, C.B. Ford, B.R. Sellman, S.A. Hammond, D.J. Freeman, P. Dennis, J-C. Soria ‚Ć, J.R. Wortman,M.R. Henn.  IOTECH. 2020 May;6(C):9-17 http://www.esmoiotech.org/article/S2590-0188(20)30013-7/pdf

Optimizing oncolytic virotherapy in cancer treatment

Harrington K, Freeman DJ, Kelly B, Harper J, Soria JC. Nat Rev Drug Discov. 2019 Sep;18(9):689-706. http://www.nature.com/articles/s41573-019-0029-0

 

Patritumab预测性生物标志物的临床翻译和验证, 抗人表皮生长因子受体3 (HER3)单克隆抗体, in Patients With Advanced Non-small Cell Lung Cancer

Mendell J, Freeman DJ, Feng W, Hettmann T, Schneider M, Blum S, Ruhe J, Bange J, Nakamaru K, Chen S, Tsuchihashi Z, von Pawel J, Copigneaux C, Beckman RA. EBioMedicine. 2015 Feb 12;2(3):264-71. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484825/

紫杉醇和卡铂联合或不联合帕尼单抗一线治疗晚期非小细胞肺癌的2期随机试验

张康，张国强，张国强，张国强，张国强，张国强，张国强。 Freeman DJ, Johnson C, Krishnan K, Johnson D. J Thoracic Oncol. 2013 Dec;8(12):1510-8. http://www.jto.org/article/S1556-0864(15)30133-7/fulltext  

基因表达谱可以预测动物异种移植模型对帕尼单抗单药治疗的反应

Boedigheimer M*, Freeman DJ*, Kiaei P, Damore MA, Radinsky R. Neoplasia. 2013 Feb;15(2):125-132. *These authors contributed equally to this work. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579315/

在人类癌症临床前模型中，帕尼单抗的肿瘤穿透和表皮生长因子受体饱和与抗肿瘤活性相关

Freeman DJ, McDorman K, Ogbagabriel S, Kozlosky C, Yang BB, Doshi S, Perez-Ruxio JJ, Fanslow W, Starnes C, Radinsky R. Mol Cancer. 2012 Jul 25;11(1):47. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499177/#__ffn_sectitle

帕尼单抗单独或联合化疗对表达表皮生长因子受体突变的非小细胞肺癌细胞系的活性

Freeman DJ，奥格巴布里尔S, Belmontes B, Juan T, Plewa C, Van G, Johnson C, Radinsky R. Mol Cancer Ther. 2009 Jun;8(6):1536-46. http://mct.aacrjournals.org/content/8/6/1536

 

单纯接受帕尼单抗治疗的转移性结直肠癌患者K-ras突变状态与临床结局的相关性

Freeman DJ， Juan T, Reiner M, Hecht JR, Meropol NJ, Berlin J, Mitchell E, Sarosi I, Radinsky R, Amado RG. Clin Colorectal Cancer. 2008 May;7(3):184-190. http://www.clinical-colorectal-cancer.com/article/S1533-0028(11)70418-2/fulltext